07:00 , Aug 7, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Infectious disease Hendra virus glycoprotein G; Nipah virus glycoprotein G Monkey studies suggest the human...
07:00 , Aug 2, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Mn2+-peptide complex for preserving immunogenicity of irradiated vaccine epitopes A radioprotective Mn2+-peptide complex could help improve the efficacy of...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Galena Biopharma, Roche deal

Galena and Roche partnered to conduct a Phase II trial of Galena's NeuVax in combination with the pharma's Herceptin trastuzumab as adjuvant treatment of breast cancer in about 300 patients not eligible for...
07:00 , Sep 26, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $2.78 to $66.15 on Friday after FDA granted accelerated approval to Soliris eculizumab to treat atypical hemolytic uremic syndrome, a rare and chronic blood disease that can lead to renal...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

RXi Pharmaceuticals, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., University of Texas M.D. Anderson Cancer Center deal

The university and its not-for-profit partner granted RXi exclusive, worldwide rights to a cancer vaccine that targets folate binding protein-E39 (FBP). RXi plans to start Phase I trials by year end in ovarian/endometrial and...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

RXi Pharmaceuticals, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. deal

RXi acquired patent rights from the foundation to develop and commercialize NeuVax for use in combination with Herceptin trastuzumab and in low-to-intermediate HER2-positive breast cancer patients not eligible for Herceptin treatment. RXi gained...
08:00 , Feb 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Neurology ...